Advertisement
Advertisement
EVMN
E
Evommune, Inc.
23.66
USDSponsored
+0.53
+2.29%
Mar 26, 15:59 UTC -4
Closed
After-Market
24.28
+0.62
+2.62%
EVMN Earnings Reports
Positive Surprise Ratio
EVMN beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Evommune, Inc. earnings per share and revenue
On Mar 05, 2026, EVMN reported earnings of -1.43 USD per share (EPS) for Q4 25, missing the estimate of -0.90 USD, resulting in a -58.71% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.62% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Evommune, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Evommune, Inc. reported EPS of -$1.43, missing estimates by -58.71%, and revenue of $0.00, 0% as expectations.
How did the market react to Evommune, Inc.'s Q4 2025 earnings?
The stock price moved up 5.62%, changed from $25.09 before the earnings release to $26.50 the day after.
When is Evommune, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Evommune, Inc.'s next earnings report?
Based on --
analysts, Evommune, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement